Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib […]
